Index S&P 500
P/E -
EPS (ttm) -2.27
Insider Own 0.93%
Shs Outstand 181.00M
Perf Week 2.43%
Market Cap 11.11B
Forward P/E 35.92
EPS next Y 1.70
Insider Trans -1.54%
Shs Float 179.82M
Perf Month 3.63%
Income -413.00M
PEG -
EPS next Q 0.14
Inst Own 86.80%
Short Float 5.04%
Perf Quarter 0.25%
Sales 4.42B
P/S 2.51
EPS this Y 340.44%
Inst Trans -6.33%
Short Ratio 5.19
Perf Half Y 13.61%
Book/sh 19.52
P/B 3.13
EPS next Y 54.50%
ROA -4.19%
Short Interest 9.06M
Perf Year 54.44%
Cash/sh 1.84
P/C 33.17
EPS next 5Y 12.00%
ROE -11.19%
52W Range 36.74 - 61.50
Perf YTD 36.01%
Dividend Est. -
P/FCF 112.24
EPS past 5Y -
ROI -4.90%
52W High -0.63%
Beta 1.15
Dividend TTM -
Quick Ratio 1.96
Sales past 5Y 12.75%
Gross Margin 21.82%
52W Low 66.34%
ATR (14) 0.58
Dividend Ex-Date -
Current Ratio 2.51
EPS Y/Y TTM 58.57%
Oper. Margin 3.51%
RSI (14) 64.22
Volatility 1.07% 0.97%
Employees 16900
Debt/Eq 1.40
Sales Y/Y TTM 4.39%
Profit Margin -9.34%
Recom 3.09
Target Price 63.43
Option/Short Yes / Yes
LT Debt/Eq 1.38
EPS Q/Q 83.10%
Payout -
Rel Volume 0.44
Prev Close 61.00
Sales Surprise -3.34%
EPS Surprise -387.61%
Sales Q/Q 4.18%
Earnings Nov 05 BMO
Avg Volume 1.75M
Price 61.11
SMA20 2.49%
SMA50 2.05%
SMA200 5.51%
Trades
Volume 771,192
Change 0.18%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-16-23 Upgrade
Robert W. Baird
Neutral → Outperform
$45 → $53
Sep-05-23 Upgrade
Argus
Hold → Buy
$62
Jul-20-23 Initiated
Wells Fargo
Equal Weight
$43
Jul-05-23 Resumed
JP Morgan
Neutral
$45
Jun-14-23 Downgrade
Jefferies
Buy → Hold
$45 → $44
May-22-23 Downgrade
JP Morgan
Overweight → Neutral
$90 → $45
May-15-23 Downgrade
Deutsche Bank
Buy → Hold
$55 → $29
May-08-23 Downgrade
BofA Securities
Neutral → Underperform
$28
Apr-17-23 Downgrade
Robert W. Baird
Outperform → Neutral
$82 → $53
Apr-14-23 Downgrade
William Blair
Outperform → Mkt Perform
Apr-10-23 Upgrade
Deutsche Bank
Hold → Buy
$79 → $88
Apr-03-23 Downgrade
Barclays
Overweight → Equal Weight
$70
Dec-19-22 Downgrade
KeyBanc Capital Markets
Overweight → Sector Weight
Nov-07-22 Downgrade
Argus
Buy → Hold
Nov-02-22 Downgrade
BofA Securities
Buy → Neutral
$125 → $60
Dec-16-21 Initiated
Barclays
Overweight
$160
Dec-10-20 Upgrade
KeyBanc Capital Markets
Sector Weight → Overweight
$120
Jun-25-20 Initiated
Argus
Buy
$100
Apr-21-20 Initiated
RBC Capital Mkts
Outperform
$65
Mar-02-20 Initiated
Deutsche Bank
Hold
Show Previous Ratings
Nov-21-24 07:19AM
Nov-19-24 10:58PM
Nov-17-24 04:52PM
Nov-13-24 12:42PM
Nov-05-24 03:12PM
08:25AM
Loading…
08:25AM
08:25AM
07:25AM
(Associated Press Finance)
07:23AM
07:00AM
Nov-04-24 03:01AM
Oct-30-24 06:05AM
03:46AM
Oct-23-24 07:05PM
07:45AM
04:40AM
Loading…
04:40AM
Oct-21-24 07:30AM
07:00AM
Oct-17-24 02:03PM
Oct-14-24 06:39AM
06:00AM
Oct-10-24 08:03AM
Sep-17-24 09:31AM
Sep-12-24 12:00PM
Sep-07-24 01:05AM
Sep-03-24 02:52PM
Aug-30-24 05:32PM
Aug-29-24 08:45AM
08:07AM
07:49AM
(Associated Press Finance)
07:30AM
Loading…
07:30AM
Aug-09-24 09:10AM
Aug-07-24 08:42AM
Jul-16-24 12:28PM
02:00AM
Jul-01-24 08:00AM
(Investor's Business Daily)
Jun-21-24 05:05PM
01:00PM
Jun-11-24 01:13PM
Jun-07-24 11:30AM
Jun-06-24 10:00AM
May-29-24 09:07AM
May-27-24 03:02AM
May-16-24 02:26PM
May-14-24 10:33AM
May-13-24 11:46AM
11:20AM
May-09-24 01:31PM
01:05AM
12:53AM
May-08-24 11:37PM
07:30PM
06:24PM
(Associated Press Finance)
04:15PM
May-03-24 10:12AM
09:50AM
(The Wall Street Journal)
08:58AM
08:36AM
08:16AM
04:17AM
04:02AM
May-02-24 01:08PM
11:31AM
08:19AM
08:02AM
06:18AM
Apr-17-24 08:19PM
Apr-16-24 09:53AM
Apr-11-24 02:21AM
Apr-10-24 11:03PM
Apr-08-24 06:31AM
06:28AM
05:55AM
Apr-05-24 11:08PM
Mar-28-24 01:15PM
Mar-11-24 12:44PM
Mar-09-24 01:00PM
Mar-08-24 07:11AM
Mar-07-24 10:41AM
10:31AM
08:00AM
Feb-27-24 10:50AM
Feb-14-24 04:43PM
Feb-13-24 12:32AM
Feb-10-24 09:53AM
Feb-09-24 11:28AM
09:30AM
09:13AM
08:37AM
08:14AM
08:11AM
(Associated Press Finance)
08:03AM
07:59AM
Feb-08-24 06:37AM
05:48AM
04:53AM
Feb-07-24 12:55PM
12:23PM
11:53AM
07:51AM
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Ryan Michelle R Director Nov 11 '24 Sale 59.70 2,800 167,160 10,835 Nov 14 02:46 PM Ryan Michelle R Director Nov 11 '24 Proposed Sale 59.70 2,800 167,160 Nov 12 11:21 AM Ferraro Joseph Anthony SVP, General Counsel, CCO Oct 18 '24 Sale 59.97 320 19,190 23,967 Oct 21 11:30 AM Ferraro Joseph Anthony Officer Oct 18 '24 Proposed Sale 59.97 320 19,191 Oct 18 03:45 PM Hawkeswood Thomas W Officer Oct 16 '24 Proposed Sale 60.57 625 37,856 Oct 16 03:41 PM McErlane David Group President, Biologics Sep 26 '24 Sale 59.97 1,994 119,580 36,304 Sep 27 12:01 PM McErlane David Officer Sep 26 '24 Proposed Sale 59.98 2,168 130,026 Sep 26 03:20 PM Hopson Ricky Pres. BioProduct Delivery, CoS Aug 02 '24 Sale 59.56 662 39,429 29,974 Aug 05 12:55 PM Gunther Scott SVP, Quality & Reg. Affairs Aug 02 '24 Sale 59.55 666 39,660 39,635 Aug 05 12:51 PM Ferraro Joseph Anthony SVP, General Counsel, CCO Aug 02 '24 Sale 59.58 608 36,225 24,287 Aug 05 12:45 PM Evoli Lisa SVP, Chief HR Officer Aug 02 '24 Sale 59.67 3,859 230,267 39,366 Aug 05 12:39 PM Gennadios Aristippos Group Pres. Pharma & Consumer Aug 02 '24 Sale 59.55 1,169 69,614 113,724 Aug 05 12:33 PM Gunther Scott Officer Aug 05 '24 Proposed Sale 58.98 554 32,675 Aug 05 11:52 AM Evoli Lisa Officer Aug 02 '24 Proposed Sale 59.12 3,895 230,274 Aug 02 03:37 PM Gunther Scott Officer Aug 02 '24 Proposed Sale 59.55 666 39,660 Aug 02 03:34 PM Hopson Ricky Officer Aug 02 '24 Proposed Sale 59.56 662 39,427 Aug 02 03:28 PM Gennadios Aristippos Officer Aug 02 '24 Proposed Sale 59.55 1,169 69,609 Aug 02 03:27 PM Hawkeswood Thomas W Officer Aug 02 '24 Proposed Sale 59.68 413 24,649 Aug 02 03:22 PM Ferraro Joseph Anthony Officer Aug 02 '24 Proposed Sale 59.58 608 36,225 Aug 02 03:13 PM Maselli Alessandro President & CEO Jul 29 '24 Sale 58.76 9,088 534,011 177,521 Jul 30 04:53 PM Hopson Ricky Pres. BioProduct Delivery, CoS Jul 29 '24 Sale 58.67 206 12,086 30,636 Jul 30 04:45 PM Gunther Scott SVP, Quality & Reg. Affairs Jul 29 '24 Sale 58.69 283 16,609 40,301 Jul 30 04:39 PM Gennadios Aristippos Group Pres. Pharma & Consumer Jul 29 '24 Sale 58.70 349 20,486 114,893 Jul 30 04:30 PM Gunther Scott Officer Jul 30 '24 Proposed Sale 58.94 235 13,851 Jul 30 11:47 AM Hawkeswood Thomas W Officer Jul 29 '24 Proposed Sale 58.83 217 12,766 Jul 29 04:22 PM Gennadios Aristippos Officer Jul 29 '24 Proposed Sale 58.70 349 20,487 Jul 29 03:34 PM Hopson Ricky Officer Jul 29 '24 Proposed Sale 58.67 206 12,087 Jul 29 03:20 PM Maselli Alessandro Officer Jul 29 '24 Proposed Sale 58.76 9,088 534,034 Jul 29 03:18 PM Gunther Scott Officer Jul 29 '24 Proposed Sale 58.69 283 16,609 Jul 29 03:13 PM Masanovich Matti SVP, Chief Financial Officer Jul 08 '24 Sale 56.74 2,993 169,823 33,871 Jul 10 04:56 PM Hopson Ricky Pres. BioProduct Delivery, CoS Jun 04 '24 Sale 54.26 1,401 76,023 20,617 Jun 05 09:35 PM Gunther Scott SVP, Quality & Reg. Affairs Mar 15 '24 Sale 56.20 387 21,749 29,506 Mar 19 01:38 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite